抗IL-6抗体治疗小鼠变应性鼻炎的作用的研究

目的：探讨IL-6 抗体治疗小鼠变应性鼻炎的作用。方法：实验动物分三组：PBS 组（正常对照组）、抗IL-6 抗体组（以抗IL-6 单 克隆抗体处理）、IgG 抗体对照组（以IgG对照抗体处理）。应用卵清蛋白（OVA）致敏建立小鼠变应性鼻炎模型,给予抗IL-6 单克 隆抗体干预,计量抗原激发后小鼠搔鼻数量。应用HE染色方法检测对小鼠鼻黏膜炎症影响,应用ELISA 法检测小鼠灌洗液中 IL-4、IFN-r含量。结果：治疗后抗IL-6 抗体组小鼠搔鼻症状相对于抗体对照组明显减轻（P<0.01)。与PBS 组比较,IgG 抗体对照组 小鼠鼻腔灌洗液中总炎性细胞数,淋巴细胞数及嗜酸性粒细胞数明显升高（P<0.05);IL-6 抗体治疗后,小鼠鼻腔灌洗液中总炎性 细胞数,淋巴细胞数及嗜酸性粒细胞数明显降低（P<0.05);IgG抗体对照组小鼠鼻腔灌洗液IL-4 含量明显升高（P<0.01),而IFN-r 含量不变（P>0.05);IL-6 抗体治疗后,IL-4 含量较IgG 抗体对照组降低（P<0.05),IFN-r含量不变（P>0.05)。结论：IL-6 抗体可有效 治疗小鼠变应性鼻炎。     

脂多糖对大鼠实验性变应性鼻炎的影响

目的研究脂多糖(Lipopolysaccharide,LPS)对实验性变应性鼻炎的影响。方法SD大鼠40只随机分4组,其中,变应性鼻炎组经腹腔注射及鼻腔滴入卵清白蛋白(OVA)致敏,建立变应性鼻炎动物模型;LPS刺激组经鼻腔滴入LPS(10μg/100μL);变应性鼻炎 LPS刺激组为大鼠激发成变应性鼻炎后再以LPS滴入鼻腔。观察各组的症状变化,如喷嚏,流涕等。行常规HE及甲苯胺蓝染色观察各组鼻黏膜炎性细胞的浸润情况,并行高倍镜下嗜酸性粒细胞计数。结果①变应性鼻炎 LPS刺激组过敏症状评分高于其余各组(P<0.01);正常对照组及LPS刺激组症状评分差异无显著性(P>0.05)。②变应性鼻炎 LPS刺激组鼻黏膜中嗜酸性粒细胞计数高于变应性鼻炎组,差异有显著性(P<0.05);正常对照组及LPS刺激组鼻黏膜中嗜酸性粒细胞计数差异无显著性(P>0.05)。结论LPS刺激可以加重变应性鼻炎的症状及鼻黏膜组织的病理学改变。     

变应性鼻炎模型小鼠鼻黏膜的形态学观察

目的:建立小鼠变应性鼻炎模型,观察小鼠鼻腔黏膜组织的重塑情况。方法:20只BALB/c小鼠被随机分为致敏组和对照组,使用卵清蛋白(OVA)诱导建立小鼠变应性鼻炎模型。通过HE染色观察小鼠鼻黏膜的大体重塑情况,吉姆萨染色观察嗜酸性粒细胞,阿辛蓝-过碘酸-希夫染色观察杯状细胞;酶联免疫吸附(ELISA)法检测小鼠血清中白细胞介素-4(IL-4)的水平。结果:小鼠变应性鼻炎模型的生物学行为评分为6.5±1.3,提示造模成功。与对照组相比,致敏组鼻腔黏膜出现上皮细胞脱落、坏死,杯状细胞增生,鳞状上皮化生,固有层和黏膜下层腺体增生、血管扩张,组织水肿,固有层内可见特征性的嗜酸性粒细胞浸润,造模后鼻腔黏膜结构存在重塑。致敏组小鼠鼻黏膜嗜酸性粒细胞计数及杯状细胞计数分别为(26.4±5.72)和(24.14±3.12),而对照组分别是(8.31±2.42)和(9.41±1.22),两组比较均具有统计学差异(P0.05);致敏组血清中白细胞介素4(IL-4)水平为(18.9±3.1)pg/ml,对照组为(8.3±1.4)pg/ml,致敏组显著高于对照组,差异有统计学意义(P0.05)。结论:通过卵清蛋白诱导建立的小鼠变应性鼻炎模型鼻腔黏膜存在组织重塑。     

Toll样受体2及Toll样受体4在大鼠实验性变应性鼻炎中的表达

目的研究Toll样受体2（Toll-like receptor2,TLR2）及Toll样受体4（TLR4）在实验性变应性鼻炎大鼠鼻黏膜中的表达及脂多糖（Lipopolysaccharide,LPS）对其表达的影响。方法SD大鼠48只随机分为正常对照组（A组）;变应性鼻炎组（B组）：经腹腔注射及鼻腔滴入卵清白蛋白（Ovalbumin,OVA）建立变应性鼻炎（Allergic rhinitis,AR）模型;变应性鼻炎＋LPS刺激组（C组）：大鼠激发成变应性鼻炎模型后再以LPS滴鼻。用逆转录聚合酶链反应（RT-PCR）方法检测鼻黏膜中TLR2 mRNA、TLR4 mRNA的表达。结果B、C组大鼠均成功激发为AR动物模型;各组鼻黏膜中均有TLR2 mRNA、TLR4 mRNA表达;各组间TLR2 mRNA的表达差异无统计学意义（P〉0．05）。B、C组TLR4 mRNA的表达较A组高（P〈0．01）;C组TLR4 mRNA表达较B组增高（P〈0．01）。结论AR大鼠有TLLR4的表达增高;LPS刺激后TLR4表达进一步增高,说明TLR4可能参与AR的发病。TLR2在AR大鼠中的表达未见增高;LPS刺激后。TLR2表达未见进一步增高,TLR2与变应性鼻炎的关系有待进一步研究。     

TAT-N15多肽治疗大鼠变应性鼻炎的实验研究

[目的]研究TAT-N15多肽治疗大鼠变应性鼻炎的抗炎症作用及机制。[方法]使用卵清蛋白(OVA)致变应性鼻炎大鼠模型,通过比较0. 1%和0. 3%TAT-N15多肽滴鼻液、0. 1%富马酸酮替芬滴鼻液对变应性鼻炎大鼠的行为学评价、组胺的组织学评价、以及鼻粘膜组织中NF-κB p65、PCNA、Ki-67蛋白表达水平,评价TAT-N15多肽滴鼻液治疗大鼠变应性鼻炎的作用。[结果]与正常对照组比较,0. 3%TAT-N15多肽滴鼻液组能减轻大鼠变应性鼻炎的症状,减少组胺释放64%,鼻腔组织病理学变化表明TAT-N15多肽滴鼻液能减少鼻粘膜组织的炎症细胞浸润,免疫组化结果表明,TAT-N15多肽能显著降低鼻粘膜组织中NF-κB p65、Ki-67和PCNA的表达水平。[结论]TAT-N15多肽能起到缓解大鼠变应性鼻炎症状的作用。     

鼻用皮质类固醇对儿童变应性鼻炎患者鼻腔粘液菌群 影响的研究

目的:探讨皮质类固醇激素糠酸莫米松对儿童变应性鼻炎(allergic rhinitis,AR)患者鼻腔粘液菌群(包括需氧菌和真菌)的影响,同时观察其临床疗效。方法:选择30例儿童AR患者作为观察组,给予糠酸莫米松进行治疗,检测其治疗前后鼻腔粘液的菌群分布情况,同时与对照组的正常儿童进行比较。结果:经糠酸莫米松治疗后,患者的症状和体征显著减轻。细菌检出率和真菌检出率方面,对照组为90.0%和3.3%,观察组治疗前为86.7%和16.7%,治疗后为93.3%和20.0%,对照组与观察组治疗前及观察组治疗前后差异均无统计学意义(P>0.05)。结论:糠酸莫米松治疗儿童变应性鼻炎,可以改善患者的临床症状,对于鼻腔粘液菌群没有显著影响。     

舌下特异性免疫治疗变应性鼻炎的临床疗效评价

目的：评价舌下特异性免疫治疗变应性鼻炎（allergicrhinitis,AR）的临床疗效,探讨提高AR疗效的治疗措施。方法：选择同期门诊及住院治疗的AR患者76例,在患者自愿的前提下,将患者分为对照组（n=40例）和观察组（n=36例）,对照组患者给予常规药物治疗措施,观察组患者在上述治疗措施的基础上加行舌下特异性免疫治疗,治疗12个月后比较两组患者变异性鼻炎症状评分、变异性鼻炎体征评分、临床疗效及不良反应的发生情况。结果：治疗前,两组患者变异性鼻炎症状评分与体征评分比较。差异均无统计学意义（P〉0．05）;治疗12个月后,两组患者变异性鼻炎症状评分与体征评分均较治疗前显著降低,差异具有统计学意义（P〈0．05）,且观察组患者变异性鼻炎症状评分与体征评分显著低于对照组,差异具有统计学意义（P〈0．05）。对照组和观察组的治疗总有效率分别为为87．5％和100．0％,差异具有统计学意义（P〈0．05）。此外,两组治疗期间不良反应的发生率比较差异无统计学意义（P〉0．05）。结论：舌下特异性免疫治疗治疗AR,其临床疗效确切且安全可靠,值得推广和深入研究。     

特异性免疫不同方式给药治疗变应性鼻炎的临床效果观察

目的:研究特异性免疫不同方式给药治疗变应性鼻炎的临床效果及安全性。方法:选取2013年4月-2015年4月我院收治的80例变应性鼻炎患者为研究对象,按照给药方式的不同分为对照组与观察组,对照组给予变应原疫苗皮下免疫治疗,观察组给予变应原滴剂舌下免疫治疗,比较两组患者的治疗效果、症状积分、体征积分、RQLQ评分的改善情况与不良反应的发生情况。结果:观察组患者治疗1年后症状积分、体征积分、RQLQ评分均显著低于对照组(P0.05),但总有效率显著高于对照组(P0.01),两组患者均无严重不良反应发生,对照组患者局部不良反应的发生率明显高于观察组(P0.01)。结论:采用皮下免疫法对变应性鼻炎的治疗效果明显优于舌下免疫治疗,可有效控制患者症状和体征,且安全性更高。     

儿童过敏性结膜炎与变应性鼻炎的相关性及鼻眼联合防治效果分析

目的：探讨儿童过敏性结膜炎与变应性鼻炎的相关性研究及鼻眼联合防治的临床效果。方法：回顾性分析300 例儿童过敏性 结膜炎与310 例儿童变应性鼻炎患者的临床资料,对儿童过敏性结膜炎与变应性鼻炎的相关性进行分析后将所有患儿随机均分 为对照组与观察组,对照组采用常规点眼的方法进行治疗,观察组则采用鼻朗喷鼻联合人工泪液点眼进行治疗。比较两组临床疗 效及不良反应情况。结果：（1）300 例过敏性结膜炎患儿中,50 例（16.67%）并发变应性鼻炎;310 例变应性鼻炎患儿中,59 例 （19.03%）并发过敏性结膜炎（P＞0.05）;（2）109 例同时并发两种疾病患儿中,均进行眼结膜与鼻粘膜的刮片检查嗜酸性粒细胞, 其中60 例（55.05%）结膜刮片与67 例（61.47%）鼻粘膜刮片检测到嗜酸性粒细胞（P＞0.05）;（3）两组治疗前后BUT 及角膜荧光素 染色评分、症状评分、临床总有效率比较差异明显（P＜0.05）。结论：儿童过敏性结膜炎与变应性鼻炎具有一定的相关性;鼻朗喷鼻 联合人工泪液点眼治疗儿童合并变应性鼻炎的临床疗效显著。     

Calpeptin通过抑制GATA3减轻变应性鼻炎大鼠炎症

摘要 目的：本研究旨在评估钙蛋白酶抑制剂calpeptin减轻变应性鼻炎大鼠炎症的作用并探讨其机制。方法：将20只雄性SD大鼠采用数字表法随机分为4组：正常组（Normal）、变应性鼻炎组（AR）、地塞米松干预AR组（DXMS+AR）、calpeptin干预AR组（Calpeptin+AR）。造模成功后,对大鼠AR症状进行行为学评分,对大鼠鼻黏膜组织切片以HE和PAS染色法观察鼻黏膜病理改变;对大鼠外周血以ELISA法检测总IgE、IL-4、IL-13水平;对大鼠鼻黏膜组织以免疫蛋白印迹法检测GATA3蛋白表达水平。单因素方差分析进行多组间比较,LSD- t检验进行组间两两比较。结果：与Normal组相比,AR组大鼠的鼻部过敏症状、鼻黏膜嗜酸粒细胞计数及外周血总IgE水平均升高,Calpeptin与地塞米松均能减轻气道炎症,减少嗜酸性粒细胞浸润,降低血清中OVA诱导的IgE的生成。探讨机制发现,酶联免疫吸附试验检测Th2细胞因子,与Normal组比较,AR组血清IL-4、IL-13水平均升高（P＜0.05）,而Calpeptin与地塞米松均能降低血清IL-4、IL-13水平（P＜0.05）。免疫蛋白印迹法检测大鼠鼻黏膜GATA3蛋白表达水平显示,与Normal组比较,AR组鼻黏膜 GATA3表达升高（P＜0.05）,而Calpeptin与地塞米松组鼻黏膜 GATA3表达均下降（P＜0.05）。结论：腹腔注射calpeptin能够减轻变应性鼻炎大鼠局部和全身过敏反应,其机制可能下调GATA3表达,影响Th2细胞的分化及细胞因子的分泌有关。     

Longitudinal study of effects of oral dosage of Bifidobacterium bifidum G9‐1 on Japanese cedar pollen‐induced allergic nasal symptoms in guinea pigs

Previous studies using experimental animal models have reported the beneficial effects of probiotics on allergic responses; however, their long‐term effects on allergic nasal symptoms in clinical settings have not yet been elucidated in detail. In the present study, a guinea pig allergic rhinitis model involving repeated inhalation challenges with a natural allergen, Japanese cedar pollen, was used to examine the longitudinal effects of Bifidobacterium bifidum G9‐1 (BBG9‐1) on allergic nasal symptoms. BBG9‐1 was administered orally once a day. Amelioration of nasal blockage was consistently observed throughout the experimental period in the BBG9‐1‐treated group. Although challenge‐induced sneezing was not significantly inhibited in the BBG9‐1‐treated group, prolonged treatment with BBG9‐1 slightly reduced the frequency of sneezing. Antigen‐specific IgE antibody production was also not inhibited in the BBG9‐1‐treated group. Increases in the numbers of eosinophils and neutrophils in nasal cavity lavage fluid collected after pollen challenge were almost completely suppressed by BBG9‐1 treatment, whereas those in mast cell mediators, histamine and cysteinyl leukotrienes were not. In contrast, increases in the levels of nitric oxide metabolites were potently suppressed. Furthermore, prolonged BBG9‐1 treatment markedly suppressed exogenous leukotriene D₄‐induced nasal blockage. Thus, prolonged oral administration of BBG9‐1 suppresses Japanese cedar pollen‐induced allergic nasal symptoms. The inhibitory mechanisms responsible may involve reductions in the responsiveness of target organs, such as endothelial cells in nasal mucosal blood vessels, to chemical mediators.     

孟鲁司特与糠酸莫米松鼻喷剂联合治疗儿童变应性鼻炎的近期疗效观察

目的：评价口服孟鲁司特和糠酸莫米松鼻喷剂联合治疗儿童变应性鼻炎的近期疗效,以优化儿童变应性鼻炎的治疗方案。方法：选择2011年4月-2012年4月在潍坊市人民医院耳鼻喉科就诊并确诊为变应性鼻炎的患儿48例,随机分为联合用药组（MM组,24例）和糠酸莫米松组（MS组,24例）。MM组患者给予糠酸莫米松喷鼻（早晨喷鼻1次,每次2喷）,孟鲁司特片口服（5mg／次,1次／天,睡前30分口服）;MS组患者给予糠酸莫米松喷鼻（早晨啧鼻2次,每次2啧）。两组的治疗疗程均为3个月,治疗后观察和比较两组患者鼻塞、鼻痒、流清涕、喷嚏等,临床症状及鼻内镜的检查结果。结果：治疗1个月后,两组治疗总有效率的差异无统计学意义（P〉0．05）;治疗3个月后,两组症状评分的改善高于1月朱（P〈0．05）;治疗3个月后,MM组的治疗总有效率显著高于MS组（P〈0．05）。结论：糠酸莫米松与孟鲁司特联合治疗儿童常年性变异性鼻炎的临床疗效优于单用糠酸莫米松治疗,且不良反应少。对于常年性变应性鼻炎患儿的治疗应以序贯性和个体化治疗为原则,最大程度发挥糠酸莫米松与孟鲁司特间的相互协同作用。     

Inhalation of toluene diisocyanate vapor induces allergic rhinitis in mice

Diisocyanates are the leading cause of occupational asthma, and epidemiological evidence suggests that occupational rhinitis is a comorbid and preceding condition in patients who develop asthma. The goal of the present studies was to develop and characterize a murine model of toluene diisocyanate (TDI)-induced rhinitis. Female C57BL/6 mice were exposed to workplace-relevant concentrations of TDI vapor via inhalation for 4 h/day for 12 days with or without a 2-wk rest period and TDI challenge. Mice exposed 12 consecutive weekdays to 50 parts per billion TDI vapor showed elevated total serum IgE and increased TDI-specific IgG titers. Breathing rates were decreased corresponding with increased inspiratory time. TDI exposure elevated IL-4, IL-5, IL-13, and IFN-gamma mRNA expression in the nasal mucosa, suggesting a mixed Th1/Th2 immune response. Expressions of mRNA for proinflammatory cytokines and adhesion molecules were also up-regulated. These cytokine changes corresponded with a marked influx of inflammatory cells into the nasal mucosa, eosinophils being the predominant cell type. Removal from exposure for 2 wk resulted in reduced Ab production, cytokine mRNA expression, and cellular inflammation. Subsequent challenge with 50 parts per billion TDI vapor resulted in robust up-regulation of Ab production, cytokine gene expression, as well as eosinophilic inflammation in the nasal mucosa. There were no associated changes in the lung. The present model shows that TDI inhalation induces immune-mediated allergic rhinitis, displaying the major features observed in human disease. Future studies will use this model to define disease mechanisms and examine the temporal/dose relationship between TDI-induced rhinitis and asthma.     

Orally administrated Lactobacillus gasseri TMC0356 and Lactobacillus GG alleviated nasal blockage of guinea pig with allergic rhinitis

Lactobacillus GG (LGG) and L. gasseri TMC0356 (TMC0356) were investigated for their ability to alleviate nasal blockage associated with allergic rhinitis using a guinea pig model. The increases in sRaw at 10 min and 5 hr after the exposure of the nasal mucosa to OVA were significantly alleviated in the guinea pigs orally administrated with LGG and TMC0356 compared with those of the control (P<0.05 and P<0.01). The total numbers of leukocytes, particularly eosinophils and neutrophils from the nasal cavity lavage fluid, and the OVA-specific IgE concentration in the serum were also decreased in the guinea pigs orally administrated with LGG and TMC0356, although the decreases were not statistically significant. These results suggest that LGG and TMC0356 can alleviate antigen-induced nasal blockage in earlyphase and late-phase inflammatory responses associated with allergic rhinitis.     

变应性鼻炎患者外周血中IL-27和Treg细胞的相关性分析

目的探讨外周血IL-27和CD4^＋CD25^＋调节性T细胞（Treg）在变应性鼻炎（AR）发病机制中的作用。方法2012年3月至7月,收集AR患者32例（AR组）和20例健康志愿者（对照组）外周血,采用流式细胞术（FCM）检测外周血中Treg细胞比例;ELISA检测血清中IL-27、IL-10和TGF-β1的水平。结果AR组Treg细胞百分率[（1．75±0．56）％]明显低于对照组[（4．76±1．75）％],两组比较的差异有统计学意义（P〈0．01）。AR组IL-27、IL-10和TGF-β1的水平分别为（24．43±16．36）pg／ml、（14．29±6．16）pg／ml、（0．34±0．04）pg／ml,均低于对照组（44．09±13．12）pg／ml、（31．32±21．20）pg／ml、（O．49±0．06）pg／ml,两组之间的差异有统计学意义（P〈0．01）。AR患者外周血中IL-27和Treg细胞百分率、IL-10、TGF-β1存在正相关（r分别为0．825,0．646,0．517,P〈0．01）,Treg细胞百分率和IL-10、TGF-β1存在正相关（r=0.622,0．738,P〈0．01）,IL-10和TGF-β1无相关性（r=0．304,P〉0．05）结论AR患者外周血中IL-27水平降低,Treg细匏百分率降低及其主要分泌因子IL-10、TGF-β1水平降低,且IL-27与Treg细胞百分率、IL-10、TGF-β1水平呈正相关,提示在AR发病中IL-27对Treg细胞可能具有免疫调节作用。     

Level of Fatty Acid Binding Protein 5 (FABP5) Is Increased in Sputum of Allergic Asthmatics and Links to Airway Remodeling and Inflammation

BackgroundThe inflammatory processes in the upper and lower airways in allergic rhinitis and asthma are similar. Induced sputum and nasal lavage fluid provide a non-invasive way to examine proteins involved in airway inflammation in these conditions.ObjectivesWe conducted proteomic analyses of sputum and nasal lavage fluid samples to reveal differences in protein abundances and compositions between the asthma and rhinitis patients and to investigate potential underlying mechanisms.MethodsInduced sputum and nasal lavage fluid samples were collected from 172 subjects with 1) allergic rhinitis, 2) asthma combined with allergic rhinitis, 3) nonallergic rhinitis and 4) healthy controls. Proteome changes in 21 sputum samples were analysed with two-dimensional difference gel electrophoresis (2D-DIGE), and the found differentially regulated proteins identified with mass spectrometry. Immunological validation of identified proteins in the sputum and nasal lavage fluid samples was performed with Western blot and ELISA.ResultsAltogether 31 different proteins were identified in the sputum proteome analysis, most of these were found also in the nasal lavage fluid. Fatty acid binding protein 5 (FABP5) was up-regulated in the sputum of asthmatics. Immunological validation in the whole study population confirmed the higher abundance levels of FABP5 in asthmatic subjects in both the sputum and nasal lavage fluid samples. In addition, the vascular endothelial growth factor (VEGF) level was increased in the nasal lavage fluid of asthmatics and there were positive correlations between FABP5 and VEGF levels (r=0.660, p<0.001) and concentrations of FABP5 and cysteinyl leukotriene (CysLT) (r=0.535, p<0.001) in the nasal lavage fluid.ConclusionsFABP5 may contribute to the airway remodeling and inflammation in asthma by fine-tuning the levels of CysLTs, which induce VEGF production.